EWA
AKRO

Evolution Wealth Advisors’s Akero Therapeutics AKRO Stock Holding History

Evolution Wealth Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-211
Closed -$5K – 155
2021
Q3 		$5K Sell
211
-322
-60% -$7.29K ﹤0.01% 495
2021
Q2 		$13K Hold
533
– – ﹤0.01% 360
2021
Q1 		$15K Hold
533
– – ﹤0.01% 338
2020
Q4 		$14K Sell
533
-182
-25% -$5.06K ﹤0.01% 307
2020
Q3 		$22K Hold
715
– – 0.01% 260
2020
Q2 		$18K Hold
715
– – 0.01% 211
2020
Q1 		$15K Buy
715
+174
+32% +$3.73K 0.01% 172
2019
Q4 		$12K Buy
+541
New +$11.2K ﹤0.01% 265

Other funds holding AKRO

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Evolution Wealth Advisors's AKRO Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Akero Therapeutics (AKRO) in Q4 2021, closing a stake of 211 shares — an estimated $5K sold.

Evolution Wealth Advisors first reported a position in AKRO in Q4 2019 and held it in 8 quarters. The position peaked at $22K in Q3 2020. 97 funds tracked by Wall St. Rank hold AKRO as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining Akero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 211 Akero Therapeutics shares in Q4 2021, an estimated $5K.
  • Evolution Wealth Advisors first reported a position in Akero Therapeutics in Q4 2019 and held it in 8 quarters.
  • Evolution Wealth Advisors's Akero Therapeutics position peaked at $22K in Q3 2020.
  • 97 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.